Tempus AI Targets $20B MRD Market with $1.5B Personalis Acquisition

summarizeSummary

Tempus AI agreed to acquire Personalis for $1.5 billion in stock, integrating its leading MRD test into Tempus' AI-enabled precision oncology platform and targeting a $20 billion market.

check_boxKey Events · M&A and Partnerships · TEM

• Acquisition of Personalis

  Tempus AI will acquire all outstanding shares of Personalis not already owned for $16.25 per share, representing a total enterprise value of $1.5 billion net of its existing stake.

• Deal Structure

  Consideration is 100% stock with a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share; Tempus may elect to pay up to 50% in cash.

• Strategic Rationale

  The acquisition integrates Personalis' ultrasensitive MRD test into Tempus' AI platform, expanding its reach across the cancer care continuum and targeting a $20 billion market opportunity.

• Personalis Momentum

  Personalis reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% increase in test volumes quarter-over-quarter.

auto_awesomeAnalysis · TEM · Technology

In a thesis-altering move, Tempus AI is acquiring Personalis in an all-stock deal valued at $1.5 billion net of its existing stake, paying $16.25 per share — a 6% premium to the last close. The transaction brings Personalis' industry-leading minimal residual disease (MRD) test under Tempus' commercial umbrella, unlocking a $20 billion market opportunity. Structured with a floating exchange ratio capped at 0.3356 Tempus shares per Personalis share, the deal gives Tempus the option to pay up to 50% in cash. Underscoring the asset's momentum, Personalis delivered preliminary Q2 revenue of $22.4 million and a 33% sequential jump in test volumes. Closing is expected in late 2026 or early 2027, pending shareholder and regulatory approvals. This acquisition significantly expands Tempus' oncology platform and creates a new growth vector in cancer monitoring.